Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system

Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system

<p style="text-align:justify;"> <b>Background:</b> Symptomatic slow-acting drugs (SYSADOA) have been largely studied over the last decade. The objective of this study is to prepare a document providing recommendations for the use of SYSADOA in osteoarthritis (OA). <br...

Descrición completa

Detalles Bibliográficos
Main Authors:	Bruyère, O, Burlet, N, Delmas, P, Rizzoli, R, Cooper, C, Reginster, J
Formato:	Journal article
Idioma:	English
Publicado:	BioMed Central 2008

Títulos similares

Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system
por: Rizzoli René, et al.
Publicado: (2008-12-01)

SYMPTOMATIC SLOW ACTING DRUGS IN THE TREATMENT OF OSTEOARTHRITIS
por: L. I. Alekseeva
Publicado: (2012-04-01)

Advantages of osteoarthritis combined treatment with symptomatic slow-acting drugs
por: E. V. Zonova
Publicado: (2021-04-01)

The use of symptomatic slow-acting drugs for osteoarthritis of the joints of the hands: Accent on microcirculation parameters
por: A. S. Trofimova, et al.
Publicado: (2024-03-01)

Multimorbidity in osteoarthritis and pleiotropic effects of slow-acting symptomatic drugs. Resolution of the multidisciplinary International Expert Council
por: V. I. Mazurov, et al.
Publicado: (2023-10-01)

Analysis of the therapeutic benefits of symptomatic slow acting drugs in osteoarthritis: emphasis on structural-modifying action
por: I. B. Belyaeva, et al.
Publicado: (2021-12-01)

Chronic back pain as a spinal osteoarthritis manifestation: rationale and practice of symptomatic slow acting drugs for osteoarthritis use
por: A. E. Karateev
Publicado: (2022-08-01)

Pharmacological treatment options for osteoarthritis: focus on symptomatic slow-acting drugs for osteoarthritis (SYSADOA) and individual patient characteristics: Resolution of the International Expert Meeting
por: A. M. Lila, et al.
Publicado: (2019-10-01)

Reduction of social coverage for symptomatic slow-acting drugs for osteoarthritis: a disinvestment initiative in Argentina, 2015-2017
por: Martín A. Urtasun, et al.
Publicado: (2021-03-01)

European guidance for the diagnosis and management of osteoporosis in postmenopausal women.
por: Kanis, J, et al.
Publicado: (2008)

European guidance for the diagnosis and management of osteoporosis in postmenopausal women (Osteoporosis International DOI: 10.1007/s00198-008-0560-z)
por: Kanis, J, et al.
Publicado: (2008)

Treatment in patients with osteoarthritis at different sites: Place of slow-acting drugs
por: N. V. Chichasova, et al.
Publicado: (2015-06-01)

European guidance for the diagnosis and management of osteoporosis in postmenopausal women (vol 19, pg 399, 2008)
por: Kanis, J, et al.
Publicado: (2008)

Combined use of non-steroidal anti-inflammatory drugs and symptomatic slow-acting drugs in musculoskeletal diseases
por: A. E. Karateev, et al.
Publicado: (2023-07-01)

Strontium Ranelate Significantly Decreases Radiological Progression Using a New Definition For Radiological Progression In Patients With Primary Knee Osteoarthritis Treated With Strontium Ranelate
por: Bruyere, O, et al.
Publicado: (2013)

Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis.
por: Bruyère, O, et al.
Publicado: (2014)

Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation.
por: Delmas, P, et al.
Publicado: (2005)

Cardiovascular safety and efficacy of the combined symptomatic slow-acting drug glucosamine and chondroitin sulfate in patients with gonarthrosis
por: A. P. Rebrov, et al.
Publicado: (2016-06-01)

SLOW-ACTING ANTI-ARTHROSIS MEDICATIONS FOR THE TREATMENT OF OSTEOARTHRITIS
por: M. S. SVETLOVA
Publicado: (2016-12-01)

STRONTIUM RANELATE PREVENTS SPINE OSTEOARTHRITIS PROGRESSION IN PATIENTS WITH PREVALENT SPINAL OSTEOARTHRITIS
por: O Bruyere, et al.
Publicado: (2007-08-01)

Exploring Future Horizons in Osteoarthritis Relief: Unveiling the Potential of Slow-Acting Drugs and Innovative Medications
por: Katarzyna Sokołowska, et al.
Publicado: (2024-02-01)

Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).
por: Rizzoli, R, et al.
Publicado: (2013)

An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis
por: Sara Tenti, et al.
Publicado: (2023-03-01)

How to define responders in osteoarthritis.
por: Cooper, C, et al.
Publicado: (2013)

Safety of oral non-selective non-steroidal anti-inflammatory drugs in osteoarthritis: What does the literature say?
por: Cooper, C, et al.
Publicado: (2019)

Clinically Meaningful Effect of Strontium Ranelate On Knee Osteoarthritis Symptoms
por: Bruyere, O, et al.
Publicado: (2012)

Lower Limb Muscle Strength and Muscle Mass Are Associated With Incident Symptomatic Knee Osteoarthritis: A Longitudinal Cohort Study
por: Nicola Veronese, et al.
Publicado: (2021-12-01)

Strontium Ranelate in Knee Osteoarthritis Trial (SEKOIA): A Structural and Symptomatic Efficacy.
por: Reginster, J, et al.
Publicado: (2012)

An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).
por: Bruyère, O, et al.
Publicado: (2014)

Changes in structure and symptoms in knee osteoarthritis and prediction of future knee replacement over 8 years.
por: Bruyere, O, et al.
Publicado: (2013)

European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) Newsletter
por: RENE RIZZOLI, et al.
Publicado: (2007-08-01)

Symptomatic delayed-acting drugs (SYSADOA): new applications
por: A. M. Lila, et al.
Publicado: (2022-05-01)

Symptom-modifying slow-acting drugs in the treatment of osteoarthritis: from molecule to clinical effect (a pharmacologist's view)
por: A. S. Dukhanin
Publicado: (2018-06-01)

Symptomatic knee osteoarthritis: Evidence for intrauterine programming
por: Jordan, K, et al.
Publicado: (2004)

Evidence for intrauterine programming in symptomatic knee osteoarthritis
por: Jordan, K, et al.
Publicado: (2005)

Recommendations for the reporting of harms in manuscripts on clinical trials assessing osteoarthritis drugs: A consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)
por: Honvo, G, et al.
Publicado: (2019)

Adherence to a Mediterranean diet is associated with lower prevalence of osteoarthritis: Data from the osteoarthritis initiative.
por: Veronese, N, et al.
Publicado: (2016)

Serum lysophosphatidylcholines to phosphatidylcholines ratio is associated with symptomatic responders to symptomatic drugs in knee osteoarthritis patients
por: Guangju Zhai, et al.
Publicado: (2019-11-01)

IMPACT OF COMPONENTS OF THE METABOLIC SYNDROME ON KNEE OSTEOARTHRITIS PROGRESSION IN THE SEKOIA STUDY
por: Eymard, F, et al.
Publicado: (2014)

HEALTH ECONOMICS IN OSTEOARTHRITIS
por: Hiligsmann, M, et al.
Publicado: (2013)